Outcome after reduced chemotherapy for intermediate-risk neuroblastoma

New England Journal of Medicine

Volumn 363, Issue 14, 2010, Pages 1313-1323

  Baker, David L ^a   Schmidt, Mary L ^b   Cohn, Susan L ^c   Maris, John M ^d   London, Wendy B ^e   Buxton, Allen ^f   Stram, Daniel ^g   Castleberry, Robert P ^h   Shimada, Hiroyuki ^g   Sandler, Anthony ⁱ   Shamberger, Robert C ^e   Look, A Thomas ^j   Reynolds, C Patrick ^k   Seeger, Robert C ^g   Matthay, Katherine K ^l  

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f CHILDREN S ONCOLOGY GROUP   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^j ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^k TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; VINDESINE; ANTINEOPLASTIC AGENT;

ARTICLE; BLEEDING; BLOOD VESSEL INJURY; CANCER STAGING; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIPLOIDY; DISEASE COURSE; DRUG DOSE REGIMEN; EVENT FREE SURVIVAL; GENE AMPLIFICATION; HEARING; HEART FUNCTION; HISTOPATHOLOGY; HUMAN; INFANT; INFECTION; KIDNEY FUNCTION; KIDNEY INJURY; LEUKEMIA; LUNG INJURY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NERVE INJURY; NEUROBLASTOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; WOUND COMPLICATION; INTENTION TO TREAT ANALYSIS; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HUMANS; INFANT; INTENTION TO TREAT ANALYSIS; NEOPLASM STAGING; NEUROBLASTOMA; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77957358855     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1001527     Document Type: Article

References (47)

1. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:895-938.
2. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 1985;313:1111-6. (Pubitemid 16216827)
3. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
4. Look AT, Hayes FA, Schuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581-91.
5. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2451-61.
6. Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-16. (Pubitemid 14055221)
7. Nickerson HJ, Matthay KK, Seeger RC, et al. Favourable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 2000;18:477-86.
8. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group Study. J Clin Oncol 2000;18:1260-8.
9. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 1998;16:1256-64. (Pubitemid 28175737)
10. Bagatell R, Rumcheva P, London WB, et al. Outcomes of children with intermediate risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 2005;23:8819-27. (Pubitemid 46211528)
11. Gurney JG, Tersak JM, Ness KK, et al. Hearing loss, quality of life and academic performance in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics 2007;120(5):e1229-e1236.
12. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82.
13. Skinner R, Pearson AD, Price L, Coulthard MG, Craft AW. The influence of age on nephrotoxicity following chemotherapy in children. Br J Cancer Suppl 1992;18:S30-S35.
14. Brock PR, Yeomans EC, Bellman SC, Pritchard J. Cisplatin therapy in infants: short and long-term morbidity. Br J Cancer Suppl 1992;18:S36-S40.
15. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
16. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
17. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993;11:1466-77. (Pubitemid 23228250)
18. Shapiro DN, Valentine MB, Row ST, et al. Detection of N-myc gene amplification by fluorescence in situ hybridisation: diagnostic utility for neuroblastoma. Am J Pathol 1993;142:1339-46.
19. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311:231-5.
20. Greenwood M. The natural duration of cancer. Rep Public Health Med Subj (Lond) 1926;33:1-26.
21. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
22. Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy and histology in 110 infants with stage DS neuroblastoma: the Pediatric Oncology Group experience - a Pediatric Oncology Group study. J Clin Oncol 1998;16:2007-17.
23. De Bernardi B, Gerrard M, Boni L, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009;27:1034-40.
24. Hero B, Simon T, Spitz R, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB 95-S and NB 97. J Clin Oncol 2008;26:1504-10.
25. Rubie H, Plantaz D, Coze C, et al. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Med Pediatr Oncol 2001;36:247-50.
26. De Bernadi B, Conte M, Mancini A, et al. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for neuroblastoma. J Clin Oncol 1995;13:884-93.
27. Bowman LC, Castleberry RP, Cantor A, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997;89:373-80.
28. Strother D, Shuster JJ, McWilliams N, et al. Results of Pediatric Oncology Group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol 1995;17:254-9.
29. Nitschke R, Smith EI, Altshuler G, et al. Post-operative treatment of non-metastatic visible residual neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:1181-8.
30. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-97.
31. Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer 1997;33:2121-5.
32. Bergeron C, Dubourg L, Chastagner P, et al. Long term renal and hearing toxicity of carboplatin in infants treated for localised and unresectable neuroblastoma: results of the SFOP NBL90 study. Pediatr Blood Cancer 2005;45:32-6.
33. English MW, Skinner R, Pearson AD, Price L, Wyllie R, Craft AW. Dose-related nephrotoxicity of carboplatin in children. Br J Cancer 1999;81:336-41.
34. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: a report of the cardiology committee of the Children's Cancer Study Group. Pediatrics 1992;89:942-9.
35. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 1994;23:86-98. (Pubitemid 24213321)
36. Kiely EM. The surgical challenge of neuroblastoma. J Pediatr Surg 1994;29:128-33.
37. Cecchetto G, Mosseri V, De Bernardi B, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG 1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005;23:8483-9. (Pubitemid 46260245)
38. Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: results of the GPOH NB97 trial. Pediatr Blood Cancer 2008;50:965-9.
39. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27:298-303.
40. Paulino AC, Mayr NA, Simon JH, Buatti JM. Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys 2002;52:1025-31.
41. Attiyeh EF, Mosse YP, Disken S, et al. Identification of genomic DNA signatures predicting relapse in low and intermediate risk neuroblastoma using a case control design and high-density SNP genotyping: a Children's Oncology Group (COG) study. J Clin Oncol 2007;25:Suppl:18S. abstract.
42. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243-53.
43. Maris JM, White PS, Beltinger CP, et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995;55:4664-9.
44. Caron H, van Shus P, deKraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-30. (Pubitemid 26030673)
45. Guo C, White PS, Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999;18:4948-57. (Pubitemid 29425301)
46. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-33.
47. Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010;102:1319-26.